Emilio Páez-Guillán, Department of Internal Medicine. Hospital da Barbanza, Ribeira, Santiago de Compostela, A Coruña, Spain María Pazo-Núñez, Internal Medicine Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela. A Coruña, Spain Mª Aurora Freire-Romero, Internal Medicine Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela. A Coruña, Spain Mª Carmen Beceiro-Abad, Internal Medicine Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela. A Coruña, Spain Lara Mateo-Mosquera, Department of Internal Medicine. Hospital da Barbanza, Ribeira, A Coruña, Spain Mª Carmen Gayol-Fernández, Department of Internal Medicine. Hospital da Barbanza, Ribeira, A Coruña, Spain Mª Jesús Isorna-Porto, Department of Internal Medicine. Hospital da Barbanza, Ribeira, A Coruña, Spain Paula Mª Pesqueira-Fontán, Internal Medicine Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela. A Coruña, Spain Manuel Taboada-Muñiz, Deparment of Anesthesiology. Hospital Clínico Universitario de Santiago de Compostela. Santiago de Compostela, A Coruña, Spain Jonathan Geovany Montoya-Valdés, Internal Medicine Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela. A Coruña, Spain Sonia Molinos-Castro, Internal Medicine Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela. A Coruña, Spain


Objective: The objective of the study was to evaluate clinical characteristics and analytical abnormalities at admission in hospitalized patients with COVID-19 and to identify which are associated with severe disease. Methods: A retrospective cohort study was performed. All adult patients admitted with COVID-19 from March 1, 2020, to May 31, 2020, were included consecutively. A descriptive analysis of clinical characteristics and analytical abnormalities at admission was made. We evaluated what comorbidities and biomarkers are associated with severe COVID-19 using a binary logistic regression model. Results: A total of 336 patients were included, 83 patients (24.7%) with severe disease. In patients with severe COVID-19, 76% were male, mean age was 71 years, and the most prevalent comorbidities were hypertension (57.8%), obesity (55.4%), dyslipidemia (50.6%), and diabetes (42.2%). In multivariate analysis, age (OR: 1.03; 95% CI 1.01-1.05; p = 0.004), male sex (OR: 2.92; 95% CI 1.62-5.27; p < 0.001), obesity (OR: 1.84; 95% CI 1.06-3.20; p = 0.030), and obstructive sleep apnea (OSA) (OR: 5.41; 95% CI 1.63-17.94; p = 0.006) were identified as comorbidities associated with severity. Patients with severe disease presented a lower arterial partial pressure of oxygen fraction and a greater inflammatory response at admission. Biomarkers associated with severe COVID-19 were lactate dehydrogenase (LDH) > 600 U/L (OR: 2.35; 95% CI 1.10-5.04; p = 0.027), serum ferritin >600 mcg/L (OR: 2.66; 95% CI 1.24-5.70; p = 0.012), and interleukin-6 (IL-6) > 40 pg/mL (OR: 4.30; 95% CI 2.04-9.04;p < 0.001). Conclusions: Patients with severe COVID-19 disease present more comorbidities and inflammatory response atadmission. Age, male sex, obesity, and OSA are associated with severity. Biomarkers at admission associated with severeCOVID-19 are LDH > 600 U/L, serum ferritin > 500 mcg/L, and IL-6 > 40 pg/mL.



Keywords: Comorbidity. Biomarkers. COVID-19. Severity.